Exhibit 99.1

OPKO Announces Third Quarter 2013 Financial and Operating Highlights

MIAMI, November 11, 2013 — OPKO Health, Inc. (NYSE: OPK), a multi-national biopharmaceutical and diagnostics company, today reported operating and financial highlights for the third quarter of 2013.

Third Quarter 2013 Financial Highlights

Net loss for the nine months ended September 30, 2013 also includes $11.0 million of other income from the sale of securities, partially offset by $10.1 million of interest expense principally related to our 2033 Senior Notes.

Business Highlights

“We again made great progress during the past quarter across many important business fronts,” said Phillip Frost, M.D., OPKO’s Chairman and Chief Executive Officer. “Our 4Kscore™ has the potential to become a transformational medical tool in the diagnosis and treatment of prostate cancer. We initiated an important pivotal clinical trial to support our planned commercial 4Kscore™ launch during the first quarter of 2014. Progress in our two Rayaldy™ clinical trials, now more than 75% enrolled, coupled with the continued development of the clinical-stage products from PROLOR and our recent strategic investments in Zebra and Arno, continue to solidify our broad development pipeline across a growing operating platform,” continued Dr. Frost. “Our strategy to make small investments in other health care companies is bearing fruit. We have monetized one of the investments at a significant profit and the value of the remaining portfolio is far in excess of our investment. These results, bolstered by broader shareholder exposure attained through our recent TASE listing, fortify the foundation for an important health care company.”

About OPKO Health, Inc.

We are a multi-national biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large and rapidly growing medical markets by leveraging our discovery, development and commercialization expertise and our novel and proprietary technologies.

This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning, including statements regarding expected financial performance, continued revenue growth and our ability to build a profitable business, our product development efforts, including whether the Phase 3 clinical trials for Rayaldy™, hGH-CTP, rolapitant, and our clinical validation study for the 4Kscore™ will be completed on a timely basis or at all and whether the data will support approval, validation and/or reimbursement for our products, our ability to enroll in our 4Kscore™ study more than 1,200 patients referred for a prostate biopsy over the course of the next few months, the expected timing for launch of our products in development, including the 4Kscore™, Rayaldy™, hGH-CTP, and citicoline, the expected timing of our clinical trials, enrollment in clinical trials, and disclosure of results for the trials, our ability to market and sell any of our products in development, including Rayaldy™, the 4Kscore™, hGH-CTP, and citicoline, whether the citicoline products will be significant contributors to Pharmadiet’s sales and earnings, the timing for submission of a NDA by TESARO for rolapitant and whether TESARO will identify a dose of IV rolapitant that provides comparable exposure to the oral formulation by year end, whether the 4Kscore™ will become a transformational medical tool in the diagnosis and treatment of prostate cancer, expectations regarding the performance of companies in which we have a strategic investment and whether we will monetize and realize a profit from our strategic investments, and whether we will continue to solidify our broad development pipeline across a growing operating platform, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, that earlier clinical results of effectiveness and safety may not be reproducible or indicative of future results, that Rayaldy™, rolapitant, hGH-CTP, and/or any of our compounds or diagnostic products under development, including our 4Kscore™ test, may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications, that currently available over-the-counter and prescription products, as well as products under development by others, may prove to be as or more effective than our products for the indications being studied. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Contacts:

Steven D. Rubin or Juan F. Rodriguez 305-575-4100